Search - tctmd.com

Displaying 1 - 20 of 177

Sort: Relevancy | Date

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

News Conference News SCCT 2025

AI-Based Coronary Plaque Analysis Can Inform Management Beyond CCTA: DECIDE Registry

Yael L. Maxwell

July 21, 2025

News Daily News

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

Michael O'Riordan

March 26, 2025

News Daily News

Ataciguat Shows Potential for Curbing Progression of Aortic Stenosis

Yael L. Maxwell

February 27, 2025

News Daily News

Invasive Testing Safely Diagnoses Microvascular Dysfunction in ANOCA

Michael O'Riordan

February 24, 2025

News Daily News

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Michael O'Riordan

February 05, 2025

News Daily News

Coronary Sinus Reducer Overlooked in Review of Stable Angina Treatments

Michael O'Riordan

January 03, 2025

News Opinion CV Team Dispatch

November 2024 Dispatch for the CV Team

L.A. McKeown

November 26, 2024

News Conference News TCT 2024

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

Michael O'Riordan

October 29, 2024

News Conference News ESOC 2024

Colchicine Misses in Secondary Stroke Prevention, but Door Not Closed Yet

Todd Neale

May 16, 2024

News Opinion CV Team Dispatch

May 2024 Dispatch for the CV Team

L.A. McKeown

May 01, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

$Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)$

Presentation ACC 2024

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Presenter: Rasha K. Al-Lamee

April 08, 2024

News Opinion CV Team Dispatch

April 2024 Dispatch for the CV Team

L.A. McKeown

April 01, 2024

News Conference News ACC 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Todd Neale

March 27, 2024

News Daily News

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

Michael O'Riordan

February 08, 2024

News Daily News

Erectile Dysfunction Drugs Don’t Mix Well With Nitrates After MI, PCI

Todd Neale

January 16, 2024

News Conference News AHA 2023

Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV

Todd Neale

November 17, 2023

News Conference News AHA 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Michael O'Riordan

November 11, 2023

Advertisement

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

AI-Based Coronary Plaque Analysis Can Inform Management Beyond CCTA: DECIDE Registry

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

Ataciguat Shows Potential for Curbing Progression of Aortic Stenosis

Invasive Testing Safely Diagnoses Microvascular Dysfunction in ANOCA

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Coronary Sinus Reducer Overlooked in Review of Stable Angina Treatments

November 2024 Dispatch for the CV Team

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

Colchicine Misses in Secondary Stroke Prevention, but Door Not Closed Yet

May 2024 Dispatch for the CV Team

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

April 2024 Dispatch for the CV Team

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER

Erectile Dysfunction Drugs Don’t Mix Well With Nitrates After MI, PCI

Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content